IP Library › Granted Patent US 12,282,013
Granted Patent B2
US 12,282,013 · App. 17/254,264 · Granted Apr 22, 2025

Ex vivo methods of screening for, and characterizing, cardiac therapeutics using preloaded cardiac tissues

Inventors: Ronald A. Li (Hong Kong, CN); Kevin D. Costa (New York, NY)
Assignee: NOVOHEART INTERNATIONAL LIMITED
G01N33/4833
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,282,013
App. No.
17/254,264
Granted
Apr 22, 2025
Kind
B2
Abstract

Provided are methods and materials for assaying known and candidate therapeutics for inotropic cardiac effects in one or more in vitro assay formats comprising preloaded cardiac tissues and/or organoids.

Claims (28)

1. A method for assaying a response of a cardiac organoid to a compound comprising:

(a) preloading a cardiac organoid in at least one organoid module by adjusting a hydrostatic pressure inside an organoid chamber to induce a change in stroke work of between 1-50% normalized to an untreated baseline to expand the cardiac organoid prior to administering a compound, wherein the cardiac organoid is housed in at least one organoid module, each organoid module comprising:

(i) a media inlet, a media outlet, and at least one wall compatible with an external detection device, wherein the cardiac organoid comprises at least one human cell, wherein the one human cell is a human embryonic stem cell, a human adult stem cell, a human induced pluripotent stem cell, a cell derived from a human tissue, or a progenitor cell of a human tissue, and wherein the cardiac organoid is in fluid communication with a fluid pump or a fluid reservoir comprising an adjustable volume of fluid, wherein the fluid pump or fluid reservoir modulates the pressure within the organoid;

(ii) a mirror arrangement for simultaneous monitoring of any biological development of the cardiac organoid in each of at least two organoid chambers; and

(iii) a detection device for observing the monitored biological development of the cardiac organoid in each of at least two organoid chambers;

(b) administering the compound to the cardiac organoid; and

(c) detecting a response of the cardiac organoid to the compound.

2. The method of claim 1 wherein the response is a positive inotropic response or a negative inotropic response.

3. The method of claim 1 wherein the compound is a pharmacological agent and the response is a response to the pharmacological agent.

4. The method of claim 1 wherein the compound is a known therapeutic.

5. The method of claim 4 wherein the known therapeutic is useful in treating a cardiac disease or disorder.

6. The method of claim 5 wherein the cardiac disease or disorder is dilated cardiomyopathy, hypertrophic cardiomyopathy, pulmonary atresia, Tetralogy of Fallot, dilated cardiomyopathy with ataxia or heterotaxy syndrome.

7. The method of claim 4 wherein the known therapeutic is useful in treating a non-cardiac disease or disorder having at least one cardiac effect.

8. The method of claim 7 wherein the non-cardiac disease or disorder is Friedreich's ataxia (FRDA), Kearns-Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia (phosphomannomutase-2 congenital defect of glycosylation Ia or PMM2-CDG-Ia), spinocerebellar ataxia, Wilson disease, Dandy-Walker syndrome, Leigh disease, mitochondria! encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), or myoclonic epilepsy with ragged red fibers (MERRF).

9. The method of claim 1 wherein the compound is a candidate therapeutic for a cardiac disease or disorder, or for a non-cardiac disease or disorder.

10. The method of claim 1 wherein the change in stroke work is between 20-30% prior to administering the compound.

11. The method of claim 1 wherein the cardiac organoid is a healthy cardiac organoid, the method further comprising a comparison of the effect of the compound on the healthy cardiac organoid to the effect of the compound on a diseased cardiac organoid to reveal at least one phenotypic difference between the healthy and diseased cardiac organoids.

12. The method of claim 11 wherein the pressure applied to the healthy cardiac organoid and the diseased cardiac organoid is the same.

13. The method of claim 11 wherein the phenotypic difference is a difference in contractile force, contractile rate, or relaxation rate.

14. The method of claim 11 wherein the diseased cardiac organoid exhibits a developed pressure of less than 2 mm H 2 O.

15. The method of claim 13 wherein the diseased cardiac organoid is from a subject with Friedrich's Ataxia.

16. The method of claim 1 wherein the cardiac organoid is electrically paced using 5 volts/cm at a frequency of 1.5 Hz.

17. The method of claim 1 wherein the stroke work is greater in the presence of the compound than in its absence, at a positive preloading of the cardiac organoid of at least 2.5 mm H 2 O.

18. The method of claim 17 wherein the difference in stroke work increases as the degree of preloading increases from 2.5 mm H 2 O to 7.5 mm H 2 O.

19. The method of claim 1 wherein the stroke work is lower in the presence of the compound than in its absence at a positive preloading pressure of the cardiac organoid of at least 2.5 mm H 2 O.

20. The method of claim 19 wherein the difference in stroke work increases as the degree of preloading increases from 2.5 mm H 2 O to 7.5 mm H 2 O.

21. The method of claim 1 wherein the organoid module further comprises a cartridge.

22. The method of claim 1 , wherein the organoid module further comprises four cartridges.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2022
From: NOVOHEART LIMITED
To: NOVOHEART INTERNATIONAL LIMITED
Reel/Frame 060756/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2021
From: LI, RONALD A.; COSTA, KEVIN D.
To: NOVOHEART LIMITED
Reel/Frame 056210/0403 →
Continuity (2)
Provisional Application 62687706 · Jun 20, 2018
Related Publication 20210263010A1 · Aug 26, 2021
References Cited (68)
US 20070238169A1 · Abilez · 2007 [cited by examiner]
US 20140342394A1 · Parker et al. · 2014 [cited by applicant]
US 20160363600A1 · Sniadecki · 2016 [cited by examiner]
US 20170002330A1 · Vunjak-Novakovic et al. · 2017 [cited by applicant]
US 20180209957A1 · Parker · 2018 [cited by examiner]
US 20180291350A1 · Murphy · 2018 [cited by examiner]
JP 3692147B2 · 2005 [cited by examiner]
WO 2018027105A1 · 2018 [cited by applicant]
Al-Mahdawi et al., Gaa repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology, Genomics, 88:580-590 (2006). [cited by applicant]
Casazza et al., The varying evolution of Friedreich's ataxia cardiomyopathy, Am. J. Cardiol., 77:895-898 (1996). [cited by applicant]
Cashman et al., Construction of defined human engineered cardiac tissues to study mechanisms of cardiac cell therapy, J. Vis. Exp., 109:e53447 (2016). [cited by applicant]
Chan et al., Label-free separation of human embryonic stem cells and their cardiac derivatives using Raman spectroscopy, Anal. Cham., 81:1324-1331 (2009). [cited by applicant]
Chen et al., Phospholamban as a Crucial Determinant of the Inotropic Response of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes and Engineered 3-Dimensional Tissue Constructs, Circ. Arrthyhm. Electrophys… [cited by applicant]
Chen et al., Shrink-film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their cardiac derivatives, Adv. Mater., 23:5785-5791 (2011). [cited by applicant]
Chow et al., Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth, Stem Cells Dev., 22:2678-… [cited by applicant]
Dixon et al., The role of iron and reactive oxygen species in cell death, Nat. Chem. Biol., 10:9-17 (2014). [cited by applicant]
Durr et al., Clinical and genetic abnormalities in patients with Friedreich's ataxia, N. Engl. J. Med., 335:1169-1175 (1996). [cited by applicant]
Edenharter et al., Overexpression of Drosophila frataxin triggers cell death in an iron-dependent manner, J. Neurogenet., 31:189-202 (2017). [cited by applicant]
Efraim, Y., et al., Biohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarction, Acta Biomaterialia, 50:220-233 (2016). [cited by applicant]
European Application No. 19822894.2, European Search Report and Opinion, mailed Feb. 23, 2022. [cited by applicant]
European Application No. 19822894.2, European Search Report and Opinion, mailed Jun. 1, 2022. [cited by applicant]
Filla et al., The relationship between trinucleotide (gaa) repeat length and clinical features in Friedreich ataxia, Am. J. Hum. Genet., 59:554-560 (1996). [cited by applicant]
Fu et al., Distinct roles of microRNA-1 and-499 in vent1icular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes, PLoS One, 6:e27417 (2011). [cited by applicant]
Fu et al., Na+/Ca2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes, Stem Cells Dev., 19:773-782 (2010). [cited by applicant]
Goffart et al., Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy, Cardiovasc Res., 64(2):198-207 (2004). [cited by applicant]
Hick et al., Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia, Dis. Model Mech., 6:608-621 (2013). [cited by applicant]
International Application No. PCT/IB19/55118, International Preliminary Report on Patentability, mailed Dec. 30, 2020. [cited by applicant]
International Application No. PCT/IB19/55118, International Search Report and Written Opinion, mailed Nov. 27, 2019. [cited by applicant]
Isnard et al., Correlation between left ventricular hypertrophy and gaa trinucleotide repeat length in Friedreich's ataxia, Circulation, 95:2247-2249 (1997). [cited by applicant]
Karakikes et al., Correction of human phospholamban RI4del mutation associated with cardiomyopathy using targeted nucleases and combination therapy, Nat. Commun., 6:6955 (2015). [cited by applicant]
Karakikes et al., Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes, Stem Cells Transl. Med., 3:18-31 (2014). [cited by applicant]
Keung et al., Non-cell autonomous cues for enhanced functionality of human embryonic stem cell-derived cardiomyocytes via maturation of sarcolemmal and mitochondrial KATP channels, Sci. Rep., 6:34154 (2016). [cited by applicant]
Kipps et al., The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood, Pediatr Cardiol., 30:306-310 (2009). [cited by applicant]
Lee et al., Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA, Int. J. Cardiol., 203:9… [cited by applicant]
Lee et al., Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells, Pflugers Arch., 466:1831-1844 (2014). [cited by applicant]
Lee, S., et al., A strain-absorbing design for tissue-machine interfaces using a tunable adhesive gel., Nature Communication, 5:1-8 ID No. 5898, (2014). [cited by applicant]
Li et al., Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells, Biomaterials, 163:116-127 (2018). [cited by applicant]
Li et al., Mechanistic basis of excitation-contraction coupling in human pluripotent stem cell-derived ventricular cardiomyocytes revealed by Ca2+ spark characteristics: Direct evidence of functional Ca2+-induced Ca2+ r… [cited by applicant]
Lieu et al., Absence of Transverse Tubules Contributes to Non-Uniform Ca2+ Wavefronts in Mouse and Human Embryonic Stem Cell-Derived Cardiomyocytes, Stem Cells Dev., 18:1493-1500 (2009). [cited by applicant]
Lieu et al., Mechanism-Based Facilitated Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes, Circ. Arrhythm. Electrophysiol., 6:191-201 (2013). [cited by applicant]
Liu et al., Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression, Am. J. Physiol. Cell Physiol., 297:C152-159 (2009). [cited by applicant]
Liu et al., Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation, Stem Cells., 12:3038-44 (2007). [cited by applicant]
Liu, X. H., et al., Biomimetic scaffolds enhancing cardiomyocyte growth and cardiac tissue development, Chinese Master's Theses Full-text Database Medicine and Health Sciences, E080-14: 36-57 (2016). [cited by applicant]
Lopaschuk et al., Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation, J. Cardiovasc Pharmacol., 56:130-140 (2010). [cited by applicant]
Luna et al., Multiscale Biomimetic Topography for the Alignment of Neonatal and Embryonic Stem Cell-Derived Heart Cells, Tissue Eng Part C Methods, 17:579-588 (2011). [cited by applicant]
Lynch et al., Management and therapy for cardiomyopathy in Friedreich's ataxia, Expert Rev Cardiovasc Ther., 10:767-777 (2012). [cited by applicant]
Martelli et al., Dysregulation of cellular iron metabolism in Friedreich ataxia: From primary iron-sulfur cluster deficit to mitochondrial iron accumulation, Front. Pharmacol., 5:130 (2014). [cited by applicant]
Miranda et al., Frataxin knockin mouse, FEES Lett., 512:291-297 (2002). [cited by applicant]
Ohya, T., et al., Simple action potential measurement of cardiac cell sheet utilizing electronic sheet, Artificial Life and Robotics., 23:321-327 (2018). [cited by applicant]
Payne et al., Cardiomyopathy of Friedreich's ataxia: Use of mouse models to understand human disease and guide therapeutic development, Pediatr Cardiol., 32:366-378 (2011). [cited by applicant]
Poon et al., Proteomic Analysis of Human Pluripotent Stem Cell-Derived, Fetal, and Adult Ventricular Cardiomyocytes Reveals Pathways Crucial for Cardiac Metabolism and Maturation, Circ. Cardiovasc Genet., 8:427-436 (201… [cited by applicant]
Poon et al., Transcriptome-Guided Functional Analyses Reveal Novel Biological Properties and Regulatory Hierarchy of Human Embryonic Stem Cell-Derived Ventricular Cardiomyocytes Crucial for Maturation, PLoS One, 8:e7778… [cited by applicant]
Puccio et al., Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and fe—s enzyme deficiency followed by intramitochondrial iron deposits, Nat. Genet., 27:181-186 (2001). [cited by applicant]
Rajagopalan et al., Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia, Mov. Disord., 25:846-852 (2010). [cited by applicant]
Ramirez et al., Pathology of intercalated discs in Friedreich cardiomyopathy, J. Am. Coll. Cardiol., 66:1739-1740 (2015). [cited by applicant]
Roquemore, E., et al., Cell-based early d rug safety testing, Euro Biotech News., 9(11-12):34-40 (2010). [cited by applicant]
Shum et al., A micropatterned human pluripotent stem cell-based ventricular cardiac anisotropic sheet for visualizing drug-induced arrhythmogenicity, Adv. Mater., 29(1):1602448 (2017). [cited by applicant]
Takamatsu, S., et al., Direct patterning of organic conductors on knitted textiles for long-electrocardiogra Scientific Report, 5:1-7 (2015). [cited by applicant]
Tang, T., et al., Theoretical model and numerical simulation of cardiac myocyte reorientation during cyclic substrate stretch, J. Tsing hua Univ. ( Sci. & Tech.)., 50:(5):660-664 (2010). [cited by applicant]
Tsou et al., Mortality in Friedreich ataxia, J. Neural. Sci., 307:46-49 (2011). [cited by applicant]
Turnbull et al., Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium, FASEB J., 28:644-654 (2014). [cited by applicant]
Wang et al., Effect of engineered anisotropy on the susceptibility of human pluripotent stem cell-derived ventricular cardiomyocytes to arrhythmias, Biomaterials, 34:8878-8886 (2013). [cited by applicant]
Wang et al., Electrophysiological properties of pluripotent human and mouse embryonic stem cells, Stem Cells, 23(10):1526-34 (2005). [cited by applicant]
Weidemann et al., The cardiomyopathy in Friedreich's ataxia—new biomarker for staging cardiac involvement, Int. J. Cardiol., 194:50-57 (2015). [cited by applicant]
Weng et al., A Simple, Cost-Effective but Highly Efficient System for Deriving Ventricular Cardiomyocytes from Human Pluripotent Stem Cells, Stem Cells Dev., 23:1704-1716 (2014). [cited by applicant]
Wilson et al., Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499, Circ. Cardiovasc Genet., 3:426-435 (2010). [cited by applicant]
Ye, G., et al., Conductive biomaterials in cardiac tissue engineering, Biotarget., 2(9):1-7 (2017). [cited by applicant]
Zhang et al., Consensus Comparative Analysis of Human Embryonic Stem Cell-Derived Cardiomyocytes, PLoS One, 10:e0125442 (2015). [cited by applicant]